Ekaterina A. Dobreva

Ekaterina A. Dobreva

Auto-generated profile, based on publicly available information

Ekaterina A. Dobreva

Endocrinology Research Centre

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2019 in Problems of Endocrinology
Verified
Journal Article
Open access
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
SMSvetlana S. Mirnaya
Svetlana S. Mirnaya
EDEkaterina A. Dobreva
Ekaterina A. Dobreva
IMIrina S. Maganeva
Irina S. Maganeva
EKElena Kovaleva
Elena Kovaleva
IDIvan I. Dedov
Ivan I. Dedov
BACKGROUND: There are no large-scale epidemiological studies on primary hyperparathyroidism (PHPT) in Russia. The high prevalence of the disease, the high risk of disability and death in this cohort of patients requires the study of the epidemiological and clinical structure of PHPT to determine the extent of medical care. AIM: Evaluate the frequency of PHPT detection and characterize its clinical forms in Russia using an online registry. METHODS: The object of the study is the database of the State Register of Patients with PHPT 1914 patients from 71 regions of the Russian Federation. New cases of the disease, as well as dynamic indicators are recorded when patients visit outpatient clinics or medical institutions. The analysis of data made at the end of December 2017 was carried out. The following parameters were evaluated: demographic and clinical indicators; indicators of phosphorus-calcium metabolism, the main forms of PHPT and its course, the primary characteristic of PHPT in hereditary syndromes and parathyroid carcinoma. Results are presented as mean and standard deviations, or medians and quartiles; descriptive statistics of qualitative attributes absolute and relative frequencies. RESULTS: the total number of patients with PHPT in the registry on 31 of December 2017 was 1914 cases (0.001% of the population of the Russian Federation). Identification of PHPT was 1.3 cases per 100 thousand of the population in Russia, 7.6 cases in Moscow, 6.1 cases per 100 thousand in the Moscow region. The average age of patients at the time of diagnosis was 55.6 10 years. The active phase of the disease was registered in 84.6% of patients (1620/1914), most of whom had a symptomatic PHPT 67.1% (1087/1620), and 32.9% a asymptomatic disease (533/1620). Symptomatic disease with visceral complications was detected in 15.8% cases (172/1087), with bone complications in 48.4% (526/1087). The mixed form of the disease was detected in 35.8% of patients with manifest form (389/1087). Normocalcemic variant PHPT (nPHPT) was registered in 14.5% cases (234/1620). Sporadic PHPT occurs in 83% of cases (1592/1914). 326 patients (17%) had a suspicion for hereditary form of the disease: average age was 31.2 12.3 years. A genetic analysis was conducted in 61 patients (3.2%): showed the mutation in the MEN1 gene in 2.9% of cases (55/1914) and the mutation in the CDC73 gene in 0.3% of cases (6/1914) (HPT-JT syndrome). Parathyroid carcinoma was confirmed in 1.8% of all patients (35/1914). Surgical treatment was performed in 64.5% of patients (1234/1914). Remission was achieved in 94% of cases (1160/1234), in 6% of cases relapse after surgical treatment or persistence of PHPT was recorded. CONCLUSION: detection of PHPT in the Russian Federation raised in comparison to 2016, which is associated with an active start of registration of patients in the regions. At this stage, it is necessary to modify the principles of registration and control, to make a platform for gathering information and calculating the necessary volumes of medical care for PHPT patients.

9 March 2023 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
EBEkaterina E. Bibik
Ekaterina E. Bibik
EDEkaterina A. Dobreva
Ekaterina A. Dobreva
AEAlina R. Elfimova
Alina R. Elfimova
APAnastasiia Pershina-Miliutina
Anastasiia Pershina-Miliutina
AEAnna Eremkina
Anna Eremkina
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Background: Components of metabolic syndrome can be observed in patients with primary hyperparathyroidism (PHPT). The link between these disorders remains unclear due to the lack of relevant experimental models and the heterogeneity of examined groups. The effect of surgery on metabolic abnormalities is also controversial. We conducted a comprehensive assessment of metabolic parameters in young patients with PHPT. Methods: One-center prospective comparative study was carried out. The participants underwent a complex biochemical and hormonal examination, a hyperinsulinemic euglycemic and hyperglycemic clamps, a bioelectrical impedance analysis of the body composition before and 13 months after parathyroidectomy compared to sex-, age- and body mass index matched healthy volunteers. Results: 45.8% of patients (n = 24) had excessive visceral fat. Insulin resistance was detected in 54.2% of cases. PHPT patients had higher serum triglycerides, lower M-value and higher C-peptide and insulin levels in both phases of insulin secretion compared to the control group (p < 0.05 for all parameters). There were tendencies to decreased fasting glucose (p = 0.031), uric acid (p = 0.044) and insulin levels of the second secretion phase (p = 0.039) after surgery, but no statistically significant changes of lipid profile and M-value as well as body composition were revealed. We obtained negative correlations between percent body fat and osteocalcin and magnesium levels in patients before surgery. Conclusion: PHPT is associated with insulin resistance that is the main risk factor of serious metabolic disorders. Surgery may potentially improve carbohydrate and purine metabolism.

12 July 2022 in Endocrine
Verified
Journal Article
Closed access
PDF file
AEAnna Eremkina
Anna Eremkina
EBE. Bibik
E. Bibik
SMS. Mirnaya
S. Mirnaya
JKJulia Krupinova
Julia Krupinova
AGA. Gorbacheva
A. Gorbacheva
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva

13 January 2021 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
ЕБЕкатерина Евгеньевна Бибик
Екатерина Евгеньевна Бибик
AEAnna Eremkina
Anna Eremkina
JKJulia Krupinova
Julia Krupinova
NKNatalia Klementieva
Natalia Klementieva
ЕДЕкатерина Александровна Добрева
Екатерина Александровна Добрева
НКНаталия Владимировна Клементьева
Наталия Владимировна Клементьева
The clinical picture of primary hyperparathyroidism (PHPT) which caused by parathyroid neoplasms often includes metabolic syndrome leading to the development of cardiovascular diseases. According to clinical studies, an increased incidence of diabetes mellitus, insulin resistance, obesity, dyslipidemia, hyperuricemia and other disorders that signifi tly affect the life span and quality are observed in patients with PHPT regardless of the form and the severity of the underlying disease. Basic research shows the potential nonclassical effects of high levels of parathyroid hormone and calcium on adipose tissue, pancreas, gastrointestinal tract and kidneys. However, the pathogenetic mechanisms of impaired carbohydrate and other types of metabolism in patients with parathyroid hyperfunction remain unclear because of the lack of relevant experimental models and the heterogeneity of patient groups. Besides, the effect of surgery on metabolic abnormalities is also controversial. Nowadays a deeper understanding of this issue is required, which can subsequently help in the creation of optimal approach to diagnosis and treatment of patients. This review covers different aspects of metabolic disorders in patients with PHPT, as well as potential key factors of their development.

1 January 2025 in Journal of Obesity
Verified
Journal Article
Open access
RKRita Khusainova
Rita Khusainova
IMIldar R. Minniakhmetov
Ildar R. Minniakhmetov
OVOlga Vasyukova
Olga Vasyukova
BYBulat Ildusovich Yalaev
Bulat Ildusovich Yalaev
Ramil SalakhovRamil Salakhov
Ramil Salakhov
NMNatalia Mokrysheva
Natalia Mokrysheva
Obesity is a chronic metabolic disease characterized by excessive accumulation or uneven distribution of fat in the body, which poses a serious threat to health. Obesity significantly increases the risk of developing сonditions such as type 2 diabetes, coronary heart disease, hypertension, obstructive sleep apnea, and some types of cancer. The prevalence of obesity, especially in childhood, has increased significantly worldwide over the past few decades. The World Health Organization predicts that 250 million children and adolescents aged 5–19 years will be obese by 2030, which indicates a global problem with far‐reaching consequences. Advances in genomic technologies have led to the identification of multiple genetic loci associated with the disease ranging from severe cases with early onset to common multifactorial polygenic forms. Epigenetic changes driven by dietary and lifestyle factors are now recognized as crucial contributors to obesity. These modifications can alter gene expression and thereby link environmental influences to the observable clinical features of the disease. Significant progress has been made in deciphering the genetic architecture of obesity, particularly in pediatric populations. However, further advancement requires integrative multiomics analyses that encompass genomic, epigenomic, transcriptomic, proteomic, metabolomic, and microbiome data. To better understand the complex molecular underpinnings and clinical variability of obesity, researchers are increasingly applying methods from machine learning and artificial intelligence. These technologies help analyze large‐scale genomic and phenotypic datasets, allowing for the identification of biological pathways involved in weight regulation. In the future, this may support the design of individualized diagnostic tools and targeted treatment plans that reflect a patient’s genetic profile, lifestyle, and environmental exposures. To implement the principles of personalized and precision medicine in the treatment of obesity, it is crucial to identify risk profiles by assessing multiple contributing factors. This approach not only enables the prediction of an individual’s risk of obesity and its associated diseases but also facilitates the optimization of treatment based on the patient’s genetic profile. This study provides a comprehensive overview of the current understanding of childhood obesity, including its prevalence, genetic determinants, and pathophysiological mechanisms. It highlights the contribution of genetic factors to hereditary and syndromic forms, the role of gene–environment interactions (including nutrition and environmental pollutants), and the influence of epigenetic modifications on metabolic disturbances associated with polygenic obesity.

1 January 2022 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
AGAnna Gorbacheva
Anna Gorbacheva
EBE.E. Bibik
E.E. Bibik
EDE.A. Dobreva
E.A. Dobreva
AEA.R. Elfimova
A.R. Elfimova
APA.S. Pushkareva
A.S. Pushkareva
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Первичный гиперпаратиреоз (ПГПТ) ассоциирован с большей частотой ряда метаболических и сердечно-сосудистых заболеваний. Оценка распространенности этих нарушений необходима для определения тактики ведения пациентов с ПГПТ. На сегодняшний день такие эпидемиологические данные в мире и в Российской Федерации лимитированы. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить распространенность и структуру сердечно-сосудистой патологии, нарушений углеводного, липидного и пуринового обмена у пациентов с ПГПТ. МАТЕРИАЛ И МЕТОДЫ Исследование проведено на базе ФГБУ «НМИЦ эндокринологии» Минздрава России в период с января 2017 по декабрь 2021 г. В исследование включены 585 пациентов, госпитализированных по поводу верифицированного ПГПТ. Пациенты распределены в 3 группы в соответствии с возрастом. В группу A (n=119) вошли пациенты от 18 до 49 лет, в группу B (n=297) — пациенты от 50 до 65 лет, в группу C (n=152) — пациенты от 66 лет и старше. Все пациенты обследованы и получили лечение согласно действующим стандартам оказания медицинской помощи и клиническим рекомендациям. РЕЗУЛЬТАТЫ Частота ожирения в исследуемых группах составляла от 17,9 до 36,8%. Повышение концентрации триглицеридов отмечено у 19,7—34,5% пациентов, липопротеинов низкой плотности — у 54,8—73,3%, гиперурикемия выявлена у 47,0—54,1%. Частота сахарного диабета статистически значимо возрастала с увеличением возраста пациентов — от 4,2% у пациентов группы A до 19,1% у пациентов группы C, как и частота артериальной гипертензии (от 29,7 до 94,0% соответственно). У пациентов группы C частота ишемической болезни сердца достигала 21,9%. ЗАКЛЮЧЕНИЕ В настоящем исследовании продемонстрирована высокая частота ряда сердечно-сосудистых заболеваний, а также патологии липидного, углеводного и пуринового обмена у пациентов с первичным гиперпаратиреозом. Однако для принятия клинических решений на основании этих данных необходимы дальнейшие исследования.